Unknown

Dataset Information

0

Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity.


ABSTRACT: The androgen receptor (AR) is the main driver of prostate cancer (PC) development and progression, and the primary therapeutic target in PC. To date, two functional ubiquitination sites have been identified on AR, both located in its C-terminal ligand binding domain (LBD). Recent reports highlight the emergence of AR splice variants lacking the LBD that can arise during disease progression and contribute to castrate resistance. Here, we report a novel N-terminal ubiquitination site at lysine 311. Ubiquitination of this site plays a role in AR stability and is critical for its transcriptional activity. Inactivation of this site causes AR to accumulate on chromatin and inactivates its transcriptional function as a consequence of inability to bind to p300. Additionally, mutation at lysine 311 affects cellular transcriptome altering the expression of genes involved in chromatin organization, signaling, adhesion, motility, development and metabolism. Even though this site is present in clinically relevant AR-variants it can only be ubiquitinated in cells when AR retains LBD suggesting a role for AR C-terminus in E2/E3 substrate recognition. We report that as a consequence AR variants lacking the LBD cannot be ubiquitinated in the cellular environment and their protein turnover must be regulated via an alternate pathway.

SUBMITTER: McClurg UL 

PROVIDER: S-EPMC5389688 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity.

McClurg Urszula L UL   Cork David M W DMW   Darby Steven S   Ryan-Munden Claudia A CA   Nakjang Sirintra S   Mendes Côrtes Leticia L   Treumann Achim A   Gaughan Luke L   Robson Craig N CN  

Nucleic acids research 20170201 4


The androgen receptor (AR) is the main driver of prostate cancer (PC) development and progression, and the primary therapeutic target in PC. To date, two functional ubiquitination sites have been identified on AR, both located in its C-terminal ligand binding domain (LBD). Recent reports highlight the emergence of AR splice variants lacking the LBD that can arise during disease progression and contribute to castrate resistance. Here, we report a novel N-terminal ubiquitination site at lysine 311  ...[more]

Similar Datasets

| S-EPMC2848969 | biostudies-literature
2023-10-05 | MSV000093051 | MassIVE
| S-EPMC3668785 | biostudies-literature
| S-EPMC3191036 | biostudies-literature
| S-EPMC9979947 | biostudies-literature
2024-07-18 | GSE238114 | GEO
| S-EPMC1904239 | biostudies-literature
| S-EPMC3176788 | biostudies-literature
| S-EPMC6801099 | biostudies-literature
| S-EPMC5668691 | biostudies-literature